BR112013023575A8 - novo derivado de octaidrotienoquinolina, composição farmacêutica compreendendo derivado, e uso destes - Google Patents
novo derivado de octaidrotienoquinolina, composição farmacêutica compreendendo derivado, e uso destesInfo
- Publication number
- BR112013023575A8 BR112013023575A8 BR112013023575A BR112013023575A BR112013023575A8 BR 112013023575 A8 BR112013023575 A8 BR 112013023575A8 BR 112013023575 A BR112013023575 A BR 112013023575A BR 112013023575 A BR112013023575 A BR 112013023575A BR 112013023575 A8 BR112013023575 A8 BR 112013023575A8
- Authority
- BR
- Brazil
- Prior art keywords
- derivative
- pharmaceutical composition
- octahydrothienoquinoline
- octahydrothienoquinoline derivative
- pharmaceutical
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011055154 | 2011-03-14 | ||
| JP2011-055154 | 2011-03-14 | ||
| PCT/JP2012/056252 WO2012124649A1 (ja) | 2011-03-14 | 2012-03-12 | 新規なオクタヒドロチエノキノリン誘導体、それを含有する医薬組成物およびそれらの用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112013023575A2 BR112013023575A2 (pt) | 2016-12-06 |
| BR112013023575A8 true BR112013023575A8 (pt) | 2018-01-16 |
| BR112013023575B1 BR112013023575B1 (pt) | 2021-12-21 |
Family
ID=46830720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013023575-6A BR112013023575B1 (pt) | 2011-03-14 | 2012-03-12 | Compostos derivados de octaidrotienoquinolina, composição farmacêutica e agente farmacêutico compreendendo os ditos compostos |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9138434B2 (pt) |
| EP (1) | EP2687532B1 (pt) |
| JP (1) | JP5563716B2 (pt) |
| KR (1) | KR101618624B1 (pt) |
| CN (2) | CN104829628B (pt) |
| AU (1) | AU2012227428B2 (pt) |
| BR (1) | BR112013023575B1 (pt) |
| CA (1) | CA2827629C (pt) |
| DK (1) | DK2687532T3 (pt) |
| ES (1) | ES2613658T3 (pt) |
| HK (1) | HK1188791A1 (pt) |
| HU (1) | HUE033449T2 (pt) |
| IL (1) | IL228318A (pt) |
| MX (1) | MX343077B (pt) |
| MY (1) | MY183288A (pt) |
| PL (1) | PL2687532T3 (pt) |
| PT (1) | PT2687532T (pt) |
| RU (1) | RU2573399C2 (pt) |
| SG (1) | SG193400A1 (pt) |
| TW (1) | TWI537274B (pt) |
| WO (1) | WO2012124649A1 (pt) |
| ZA (1) | ZA201306905B (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6166990B2 (ja) * | 2012-09-12 | 2017-07-19 | キッセイ薬品工業株式会社 | オクタヒドロチエノキノリン誘導体の製造方法及びその製造中間体 |
| US9585885B2 (en) | 2012-12-10 | 2017-03-07 | Kissei Pharmaceutical Co., Ltd. | Substituted pyrido[2,3-g]quinazolines as dopamine D2 receptor agonists |
| WO2014112492A1 (ja) * | 2013-01-17 | 2014-07-24 | キッセイ薬品工業株式会社 | 新規なオクタヒドロキノリン誘導体、それを含有する医薬組成物およびそれらの用途 |
| KR102169337B1 (ko) | 2018-08-22 | 2020-10-23 | 주식회사 도원엔바이로 | 질소와 인의 흡착형 세라믹 미생물 담체 및 이의 제조방법 |
| EP4177257A1 (en) | 2020-07-06 | 2023-05-10 | Kissei Pharmaceutical Co., Ltd. | Succinate of octahydrothienoquinoline compound, and crystals thereof |
| JPWO2022075347A1 (pt) * | 2020-10-07 | 2022-04-14 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH507249A (de) | 1968-05-31 | 1971-05-15 | Sandoz Ag | Verfahren zur Herstellung von 2-Brom-a-ergokryptin |
| BG17785A3 (pt) | 1970-08-14 | 1973-12-25 | ||
| US4166182A (en) | 1978-02-08 | 1979-08-28 | Eli Lilly And Company | 6-n-propyl-8-methoxymethyl or methylmercaptomethylergolines and related compounds |
| DK268979A (da) | 1979-01-22 | 1980-07-23 | Lilly Co Eli | Fremgangsmaade til fremstilling af octahydro-2h-pyrrolo (3,4-g)quinoliner |
| US4526892A (en) | 1981-03-03 | 1985-07-02 | Farmitalia Carlo Erba, S.P.A. | Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas |
| US4452808A (en) | 1982-12-07 | 1984-06-05 | Smithkline Beckman Corporation | 4-Aminoalkyl-2(3H)-indolones |
| US4501890A (en) * | 1983-09-26 | 1985-02-26 | Eli Lilly And Company | Trans-(±)-2,4,6-substituted-5,5a,6,7,8,9,9a,10-octahydro-pyrimido[4,5-g]quinolines |
| US4537893A (en) * | 1984-04-27 | 1985-08-27 | Eli Lilly And Company | Octahydrothiazolo[4,5-g]quinolines and use as prolactin secretion inhibitors |
| ATE45735T1 (de) | 1984-12-22 | 1989-09-15 | Thomae Gmbh Dr K | Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arnzneimittel. |
| US4826986A (en) | 1986-06-16 | 1989-05-02 | Eli Lilly And Company | 6-Oxo-trans-octa- and decahydroquinolines |
| US5057515A (en) * | 1989-07-24 | 1991-10-15 | Eli Lilly And Company | Method for agonizing a dopamine receptor |
| US7026484B2 (en) * | 2001-02-23 | 2006-04-11 | Ligand Pharmaceuticals Incorporated | Tricyclic androgen receptor modulator compounds and methods |
| JP2005129430A (ja) | 2003-10-27 | 2005-05-19 | Konica Minolta Holdings Inc | 光電変換材料用半導体、光電変換素子及び太陽電池 |
-
2012
- 2012-03-09 TW TW101108043A patent/TWI537274B/zh active
- 2012-03-12 CA CA2827629A patent/CA2827629C/en active Active
- 2012-03-12 CN CN201510116497.8A patent/CN104829628B/zh active Active
- 2012-03-12 AU AU2012227428A patent/AU2012227428B2/en active Active
- 2012-03-12 EP EP12758328.4A patent/EP2687532B1/en active Active
- 2012-03-12 DK DK12758328.4T patent/DK2687532T3/en active
- 2012-03-12 BR BR112013023575-6A patent/BR112013023575B1/pt active IP Right Grant
- 2012-03-12 ES ES12758328.4T patent/ES2613658T3/es active Active
- 2012-03-12 KR KR1020137026327A patent/KR101618624B1/ko active IP Right Grant
- 2012-03-12 JP JP2013504717A patent/JP5563716B2/ja active Active
- 2012-03-12 RU RU2013145799/04A patent/RU2573399C2/ru active
- 2012-03-12 WO PCT/JP2012/056252 patent/WO2012124649A1/ja active Application Filing
- 2012-03-12 PT PT127583284T patent/PT2687532T/pt unknown
- 2012-03-12 CN CN201280013522.4A patent/CN103443106B/zh active Active
- 2012-03-12 HU HUE12758328A patent/HUE033449T2/en unknown
- 2012-03-12 US US14/002,533 patent/US9138434B2/en active Active
- 2012-03-12 MY MYPI2013701637A patent/MY183288A/en unknown
- 2012-03-12 MX MX2013010587A patent/MX343077B/es active IP Right Grant
- 2012-03-12 SG SG2013068242A patent/SG193400A1/en unknown
- 2012-03-12 PL PL12758328T patent/PL2687532T3/pl unknown
-
2013
- 2013-09-09 IL IL228318A patent/IL228318A/en active IP Right Grant
- 2013-09-13 ZA ZA2013/06905A patent/ZA201306905B/en unknown
-
2014
- 2014-02-28 HK HK14102023.1A patent/HK1188791A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SMT201700008B (it) | Composizione farmaceutica | |
| BR112014001255A2 (pt) | composto, uso de um composto, combinação, e, composição farmacêutica | |
| BR112014013760A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| BR112015000420A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| CO6801774A2 (es) | Compuestos de benzotiazol y su uso farmacéutico | |
| DK2694038T3 (da) | Farmaceutisk sammensætning | |
| BR112013008259A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BR112014005669A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| BR112013011448A2 (pt) | composto, composição farnmacêutica, e, uso do composto | |
| DK3246018T3 (da) | Farmaceutisk sammensætning | |
| BR112013015397A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BR112014010290A2 (pt) | composição farmacêutica, métodos, composições e usos | |
| BR112014003567A2 (pt) | composto, uso de um composto, e, composição farmacêutica | |
| CO7020907A2 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmacéuticas y métodos de uso de los mismos | |
| BR112014001991A2 (pt) | certos inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso dos mesmos | |
| BR112012031226A2 (pt) | composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica | |
| BR112013014644A2 (pt) | composição farmacêutica e complexo | |
| BR112013030302A2 (pt) | composto, composição farmacêutica, uso de um composto, combinação de um composto e dispositivo | |
| CO6970609A2 (es) | Composición farmacéutica y métodos de uso de derivados de 4-pregenen-11ß-17-21-triol-3,20-diona | |
| EE201300005A (et) | Ravimkoostis | |
| BR112014013177A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| BR112014013178A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| BR112013023575A8 (pt) | novo derivado de octaidrotienoquinolina, composição farmacêutica compreendendo derivado, e uso destes | |
| BR112013017267A2 (pt) | formulação de lipossomas, suspensão e composição farmacêutica | |
| BR112012031967A2 (pt) | composto, uso de um composto, combinação de um composto e composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/03/2012, OBSERVADAS AS CONDICOES LEGAIS. |